Mucocutaneous side effects of gefitinib

Background: Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein which is expressed in various tissues. Aberrant EGFR signaling plays an important role in carcinogenesis. Gefitinib, an EGFR inhibitor, is a promising drug in treatment of various malignancies. Awareness about the various mucocutaneous side effects of gefitinib will help in optimum management. Hence, we decided to conduct this study. Materials and Methods: We did a descriptive study and observed the various cutaneous side effects in 40 patients who were treated with gefitinib in a tertiary care center in South Kerala. Results: Dermatological adverse reactions were observed in 87.5% of our patients, the most common being dryness and pruritus in 67.5% and 65% of patients, respectively. Rashes were of Grade 1/2 severity in most of our cases. Conclusions: Cutaneous reactions, though common, were mild in majority of our patients. Studies with more sample size and follow-up are needed to improve our knowledge.